# Xcellerate Investigator Portal: A New Web-Based Tool for Online Delivery of Central Laboratory Data, Reports, and Communications to Clinical Sites

SLAS Technology 2020, Vol. 25(5) 427–435 © The Author(s) 2020



Louis Norton<sup>1</sup>, Joseph Ciervo<sup>1</sup>, Victor S. Lobanov<sup>1</sup>, and Dimitris K. Agrafiotis<sup>1,2</sup>

#### Abstract

Covance Drug Development produces more than 55 million test results via its central laboratory services, requiring the delivery of more than 10 million reports annually to investigators at 35,000 sites in 89 countries. Historically, most of these data were delivered via fax or electronic data transfers in delimited text or SAS transport file format. Here, we present a new web portal that allows secure online delivery of laboratory results, reports, manuals, and training materials, and enables collaboration with investigational sites through alerts, announcements, and communications. By leveraging a three-tier architecture composed of preexisting data warehouses augmented with an application-specific relational database to store configuration data and materialized views for performance optimizations, a RESTful web application programming interface (API), and a browser-based single-page application for user access, the system offers greatly improved capabilities and user experience without requiring any changes to the underlying acquisition systems and data stores. Following a 3-month controlled rollout with 6,500 users at early-adopter sites, the Xcellerate Investigator Portal was deployed to all 240,000 of Covance's Central Laboratory Services' existing users, gaining widespread acceptance and pointing to significant benefits in productivity, convenience, and user experience.

## **Keywords**

clinical trial, investigator portal, central laboratory, laboratory results, Xcellerate

## Introduction

The operation of a central laboratory, which manages clinical trial testing for a variety of internal and external testing centers, requires a set of specialized systems to ensure rapid and accurate capture and provisioning of results to investigational sites and trial sponsors. These types of systems differ from traditional Laboratory Information Management Systems (LIMS)<sup>1</sup> because the testing requirements and result reporting are primarily protocol- rather than sampledriven. They also differ from traditional Clinical Trial Management Systems (CTMS)<sup>2</sup> in that very detailed tracking of both operational and patient data must be managed and reported to multiple external parties. Covance's Central Laboratory Services (CLS)<sup>3</sup> business is managed by a collection of information management systems implemented and integrated throughout time. While the labs themselves use LIMS to manage instruments and laboratory workflow, the core study and data management platform is Zavacor, a proprietary transactional system that manages the testing aspects of a clinical trial, including kit ordering, test results, lab reports, and alerts. This legacy system was designed to send lab reports and alerts to investigators via fax. Setting up a new study in Zavacor requires a comprehensive protocol definition that includes visit and test schedules, alert specifications, and information about all participating sites and investigators. To isolate data reporting and transfer processes from the core laboratory operations, data are exported to two data warehouses (one containing protocol information and the other containing laboratory data) that are used

<sup>2</sup>Novartis Institutes for Biomedical Research, Cambridge, MA, USA

Received May 20, 2020, and in revised form June 13, 2020. Accepted for publication June 18, 2020.

#### **Corresponding Author:**

Louis Norton, Covance, the Drug Development Division of LabCorp, 210 Carnegie Center, Princeton, NJ 08540, USA. Email: louis.norton@covance.com

 $<sup>^{\</sup>rm I}{\rm Covance},$  the Drug Development Division of LabCorp, Princeton, NJ, USA

for web access and data transfers. Throughout time, a series of applications was developed to meet the needs of various internal and external user communities requiring access to laboratory data. The data warehouses were designed with the ability to contain authorization and access information for each user to ensure proper enforcement of the blinding rules prescribed by the protocol. A significant gap remained, however, in the services provided to investigational sites. A web application previously implemented to provide reporting and document access had substantial limitations in functionality, scalability, and performance.

This legacy application, known as eSiteAccess (ESA), was designed to provide reporting and document access using a generalized design that attempted to simultaneously satisfy the needs of four distinct user roles: external site investigators, external sponsors, internal application support, and internal document publishers. In 2017, we set out to rewrite the investigator-facing modules of the application and create a new portal specifically optimized for a singleinvestigator user role using modern web architecture concepts and design. A major architectural constraint of this effort was the need to continue to support the legacy applications for the other user roles as well as for investigators using older versions of browsers that do not support modern web technologies. All existing supporting services and database structures also needed to be maintained with minimal enhancements until all legacy applications could be replaced throughout time. Most importantly, the new application needed to provide substantial improvements in usability and reliability for the external sites.

The investigator portal presented here is part of a broader clinical trial management suite, known as Xcellerate, that uses advanced data integration, analytics, and visualization capabilities to improve patient safety, data quality, and protocol compliance throughout the clinical development process and enable greater transparency and oversight of study conduct and performance.<sup>4-9</sup> Inspired from previous work in discovery,<sup>10</sup> clinical,<sup>11,12</sup> and outcomes research,<sup>13</sup> this solution consists of a number of end-user applications connected to a clinical data repository that supports near-realtime acquisition, mapping, and integration of clinical trial data from any germane source, including laboratory test results, the subject matter of the present work. The Xcellerate Investigator Portal leverages the same architectural and web design principles to provide secure online access to laboratory results, manuals, and training materials through an intuitive interface that enhances user adoption, productivity, and collaboration.

# Methods

The application design was informed from our in-depth understanding of the current use cases and the anticipated need to incrementally expand the portal's capabilities throughout time. For the initial release, we identified the following primary use cases for the site investigator role:

- Receive, read, and print patient lab reports, including result alerts, lab results, data revision notifications, and test cancellation notifications. This is the most important use case because it is directly related to ensuring patient safety and is also a routine daily activity of investigational sites.
- Receive and read lab manuals and study training materials, site communications from Covance or the sponsor, and other general non-study-specific content, including general manuals, training materials, communications, and announcements.
- 3. View and search all site lab test results, single-testresult trends among patient visits, single-subject lab test results among all visits, and multiple-test-result trends for a single patient throughout all visits.
- 4. Manage personal notification and view preferences.
- 5. Manage and reset password.

An additional key requirement that was identified was the ability for internal staff to emulate a user, allowing support personnel to view the application exactly as an investigator would see it to be able to resolve the most common user questions or issues on first contact.

The application is also required to meet standard clinical trial data security requirements, ensuring that subject information, which includes health information and sensitive test results, is made available only to specifically authorized investigator site personnel. Subject data are de-identified using trial-specific subject identifications, and the system is not subject to HIPAA (Health Insurance Portability and Accountability Act of 1996) compliance requirements.

## Build versus Buy Analysis

On the surface, the identified use cases and high-level requirements were similar to those frequently met by commercial off-the-shelf (COTS) document management, content management, and portal frameworks. Our detailed requirements and business logic, however, would require extensive customization to any such COTS platform and force us into a development paradigm that would limit our ability to achieve our product vision. Most commercial frameworks marketed for these purposes are Java-based, which is not our preferred development language. In addition, we had already developed extensive web-based visualization and analytic software assets that we could leverage to quickly bootstrap a custom product to meet our specific needs. Finally, from a strategic perspective, we estimated that a custom, fit-for-purpose solution would be cheaper and easier to maintain, enhance, and support in the long term.

COVANCE. Investigator Portal	General General Training Help Louis Norton マ LOGOUT Manuals Communications Materials
Search by sponsor, protocol or investigator	Order by Protocol   Announcements
All Studies	We want your feedback!!
Covance Central Laborat ☆ Covance Central Laborat ☆	Welcome!! Exciting Newsi Recorded Demonstrations Now Available
eSITE TST eSITE TST Matthew Durkee (Inv) (Dr Durkee) Amanda Lenz (Dr Lenz)	Japanese Xcellerate Investigator Portal 01 to 31 Jan 201
LAB REPORTS     6 LAB REPORTS	
19 LAB MANUALS 19 LAB MANUALS	
SITE COMMUNICATIONS     SITE COMMUNICATIONS	
4 TRAINING MATERIALS     3 TRAINING MATERIALS	
	Common Links
	XIP Demonstration
	XIP Overview
	eSA Demonstration
	eSA Overview
	Xcellerate Investigator Portal- User Survey
	Kit Resupply Ordering
	US Sites Only: Create a UPS Express Critical Shipping Label
	inSITE Blog
	Global Central Laboratory Certifications
	Customs Closed/ Public Holidays Calendar

Figure 1. Xcellerate Investigator Portal (XIP) landing page.

## User Interface

The design of the front end focused on building an easy-touse, robust, and highly performant interface optimized for the site investigator role (including their supporting staff). We borrowed design patterns and ideas from popular internet and mobile applications that would be familiar to our diverse and global audience. Visualizations are also a key enabling feature in all of the Xcellerate applications; for the Xcellerate Investigator Portal (XIP), the primary focus was on assisting investigators in monitoring patient safety. The key application views are summarized below.

The application landing page uses a familiar card layout concept to provide easy access to all the studies accessible to that individual user (**Fig. 1**). Besides study identification information, each card also displays the counts of unread documents in the key document categories to facilitate the identification of new information. Simple search, sorting, and favorites features are also provided. The application toolbar, accessible from every page, provides links to general non-study information and also displays notifications for new, unread content.

Notification count indicators, similar to those displayed in mobile apps and on social networking sites, are used through the application to notify the user of new, unread content. All user content downloads are logged and may be reported to study sponsors for compliance purposes. Unread content indicators are used on the landing page, the application toolbar, and the individual study pages to assist the user with compliance. When content is required to be read by only a single user at a site for compliance purposes, a status indicator is provided to show if another user from the same trial site has downloaded that content.

As previously mentioned, the primary use cases of the application involve investigator and site staff receiving, reviewing, and possibly printing and/or saving trial test results and result alerts. We use the familiar pattern of a web-based email application inbox, specifically Gmail, as the interface for users to view and access new and historical content (**Fig. 2**). This is a friendly tabular format with information sorted in reverse chronological order by default and using bold font to indicate unread content. In addition, bulk action features are provided to assist users with repetitive tasks of downloading and printing reports. Simple search and common filters also allow easy retrieval of content. This common inbox pattern is consistently used in all views in which the user receives and accesses document-type content.

Prior to XIP, lab test results could be accessed by investigators only via legacy faxes or as PDF reports. XIP adds online viewing of these data to assist the investigator in identifying trends that may provide additional insights into patient safety. These data can be displayed either at the site level or for an individual subject. Both Excel-like tabular

(- но	ME	Group b	by None	✓ All Report Type	es 👻					🗸 docur	ment has been read
A	Lab Reports	Search				Unread Only					Unread: 0 of
٦	Lab Manuals (19)	Select	Status	Subject	Type	Visit	▼ Collected Date	Accession	Posted	Download	
	Site Actions		~	020 - AAA	Data Rev	VISIT 1	Apr 12, 2015	6500723305	Nov 5, 2017 6:10 AM	ENGLISH	0
AL.	Site Communications		~	020 - AAA	Lab Result	VISIT 1	Apr 12, 2015	6500723305	Nov 5, 2017 6:10 AM	ENGLISH	0
_	Testala a Manufala		~	020 - AAA	Lab Result	VISIT 1	Apr 12, 2015	6500723305	Nov 5, 2017 6:10 AM	ENGLISH	0
21			~	010 - ∭	Lab Result	VISIT 2	Dec 1, 2014	6500001895	Nov 5, 2017 6:10 AM	ENGLISH	0
$\propto$	Standard Test Results		~	010 - JJJ	Lab Result	VISIT 2	Dec 1, 2014	6500001895	Nov 5, 2017 6:10 AM	ENGLISH	0
1	Microbiology Results		~	010 - JJJ	Alert	VISIT 1	May 10, 2014	Y110685	Nov 5, 2017 6:10 AM	ENGLISH	0
	Subjects		~	010 - JJJ	Lab Result	VISIT 1	May 10, 2014	Y110685	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	010 - JJJ	Lab Result	VISIT 1	May 10, 2014	Y110685	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	010 - JJJ	Cancella	VISIT 1	May 10, 2014	Y110685	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	009 - 111	Alert	VISIT 1	May 7, 2014	Y110586	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	008 - HHH	Alert	VISIT 1	May 7, 2014	Y107894	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	008 - HHH	Lab Result	VISIT 1	May 7, 2014	Y107894	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	009 - 111	Lab Result	VISIT 1	May 7, 2014	Y110586	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	009 - 111	Lab Result	VISIT 1	May 7, 2014	Y110586	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	009 - 111	Lab Result	VISIT 1	May 7, 2014	Y110586	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	008 - HHH	Lab Result	VISIT 1	May 7, 2014	Y107894	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	008 - HHH	Lab Result	VISIT 1	May 7, 2014	Y107894	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	008 - HHH	Cancella	VISIT 1	May 7, 2014	Y107894	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	001 - HFJ	Lab Result	VISIT 2	Jun 30, 2013	M174171	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	001 - HFJ	Lab Result	VISIT 2	Jun 30, 2013	M174171	Nov 5, 2017 6:10 AM	ENGLISH	Θ
			~	003 - BTD	Alert	VISIT 1	Jun 27, 2013	L726391	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	003 - BTD	Lab Result	VISIT 1	Jun 27, 2013	L726391	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	70539	Alert	Month 7	Jan 18, 2010	L718385	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	70539	Alert	Month 7	Jan 18, 2010	L718385	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	70539	Lab Result	Month 7	Jan 18, 2010	L718385	Nov 5, 2017 6:10 AM	ENGLISH	0
			~	306790 - M-T	Lab Result	Screening	Dec 16, 2009	M174434	Nov 5, 2017 6:10 AM	ENGLISH	0
			./	306790 - M-T	I ah Result	Screening	Dec 16 2009	M174434	Nov 5 2017 6-10 AM	FNGLISH	0

Figure 2. Xcellerate Investigator Portal (XIP) lab reporting list view.

views and visualizations are used to provide convenient and insightful views of all data collected at the site.

The standard test results view (**Fig. 3**, top) displays all of a site's test results in a user-friendly tabular view. The application's tabular control provides several options to help find relevant results, including sortable columns, grouping, simple search, visual indicators, unit selection, field-level filtering, saved searches, and export to Excel or CSV (comma-separated values) files. Also provided is the ability to drill down to subject views. In addition to standard test results, some protocols require the presentation of microbiology test results. These data need to be viewed in a unique hierarchical layout, so a separate view was created for the data, as shown at the bottom of **Figure 3**.

To view test result trends for multiple subjects throughout visits, we added a standard test results trend view, as shown in **Figure 4**. This view allows plotting the results of a single lab test for a series of subjects among all visits, normalized in time by starting each patient curve at the initial screening visit. Chart symbols are color-coded by flag value, which usually indicates results that are higher or lower than the normal reference range. Hovering over a subject's data point displays the specific subject's reference range, and clicking a data point drills down to the subject's lab results view.

The subject lab results view (Fig. 5, top) provides a way to view all of a subject's test data in a convenient tabular form organized by visit and test types. Like other test views, many features are provided to help the user find relevant information, including simple search, flagged values, indicators, a flagged values filter, and export to Excel and CSV files. In addition, drill-up capabilities are provided to help compare test results from other patients.

The subject test trends view (**Fig. 5**, bottom) displays test trends for a single patient's test results throughout all visits. The data are plotted as aligned small multiple charts, and data points are colored to indicate flagged values, aiding the investigator to view and correlate trends that may help monitor patient safety. Simple search, test group filtering, and a flagged test filter are provided to isolate relevant information.

## Logical Architecture

As mentioned above, XIP leverages the proven web application architecture used for other dashboard and reporting applications in the Xcellerate informatics suite. This is a standard, three-tier architecture composed of a data layer, application layer, and presentation layer (**Fig. 6**). The data layer consists of the existing relational data warehouses for protocol information and laboratory test result information. A new application-specific database was created to store application-specific configuration data and materialized views for performance optimizations. The application layer

	results should not be used f	presented in or patient di	n on-screen results is not int agnosis, treatment decision	ended to be a re s or submission t	placement of the official L to regulatory bodies.	ab Results, Alerts, Data Revisio	ns and Cancellati	ons found in	the Lab Reports section	on of this soft	tware application. On-s	creen
A	My Filters:		•• show filters 🗸									
5	TEST RESULTS TREN	DS									SI Units	
										-		
			Group by	None 👻			× Canceled r	esult R [	ata revision occurred	局 Admir	histrative Question	
-	Subject	Visit	Collected Time	Accession	Test Group	Test	Value	Flags	Comments	Range	Units	
~	020 - AAA 43 years Male *	VISIT 1	Apr 12, 2015 8:00 AM	6500723305	ELECTROLYTE PANEL	Magnesium	0.98			0.62 - 1.27	mmol/L	
	020 - AAA 43 years Male R	VISIT 1	Apr 12, 2015 8:00 AM	6500723305	ELECTROLYTE PANEL	Serum Potassium	4.0			34-54	mmol/L	
**	020 - AAA 43 years Male R	VISIT 1	Apr 12, 2015 8:00 AM	6500723305	ELECTROLYTE PANEL	Serum Ricarbonate	27.0			17 - 30.6	mmol/l	
	020 - AAA 43 years Male R	VISIT 1	Apr 12, 2015 8:00 AM	6500723305	ELECTROLYTE PANEL	Serum Chloride	100			94 - 112	mmol/L	
	020 - AAA 43 years Male R	VISIT 1	Apr 12, 2015 8:00 AM	6500723305	HEMOGLOBIN A1C	Hemoglobin A1c,Variant(-70	) 6.5	н		<6.5%		
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	ELECTROLYTE PANEL	Magnesium	×					
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	ELECTROLYTE PANEL	Serum Sodium	×					
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	ELECTROLYTE PANEL	Serum Potassium	×					
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	ELECTROLYTE PANEL	Serum Bicarbonate	×					
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	ELECTROLYTE PANEL	Serum Chloride	×					
	010 - JJJ 48 years Male	VISIT 2	Dec 1, 2014 10:00 AM	6500001895	LACTIC ACID	Lactate, NaFl/KOx pl	×					
	010 - JJJ 48 years Male	VISIT 1	May 10, 2014 8:00 AM	Y110685	ELECTROLYTE PANEL	Magnesium	0.21	L		0.62 - 1.27	mmol/L	
	010 - JJJ 48 years Male	VISIT 1	May 10, 2014 8:00 AM	Y110685	ELECTROLYTE PANEL	Serum Sodium	122	LT		132 - 147	mmol/L	
	010 - JJJ 48 years Male	VISIT 1	May 10, 2014 8:00 AM	¥110685	ELECTROLYTE PANEL	Serum Potassium	6.1	HT		3.4 - 5.4	mmol/L	
	010 - JJJ 48 years Male	VISIT 1	May 10, 2014 8:00 AM	1110685 V110685	ELECTROLYTE PANEL	Serum Bicarbonate	93	H		94.112	mmol/L	
	010 - JJJ 40 years Male	VISIT 1	May 10, 2014 8:00 AM	V110685	HEMOGLOBIN A1C	Hemoglobin A1c Variant/ 70	95 \ X	ь. -		94 - 11Z	mmol/L	
	008 - HHH 49 years Male	VISIT 1	May 7, 2014 8:00 AM	Y107894	ELECTROLYTE PANEL	Magnesium	0.49 R	L		0.62 - 1.27	mmol/l	
	008 - HHH 49 years Male	VISIT 1	May 7, 2014 8:00 AM	Y107894	ELECTROLYTE PANEL	Serum Sodium	122 R	LT		132 - 147	mmol/L	
	008 - HHH 49 years Male	VISIT 1	May 7, 2014 8:00 AM	Y107894	ELECTROLYTE PANEL	Serum Potassium	6.1 R	HT		3.4 - 5.4	mmol/L	
	008 - HHH 49 years Male	VISIT 1	May 7, 2014 8:00 AM	Y107894	ELECTROLYTE PANEL	Serum Bicarbonate	32.0 R	н		17 - 30.6	mmol/L	
	008 - HHH 49 years Male	VISIT 1	May 7, 2014 8:00 AM	Y107894	ELECTROLYTE PANEL	Serum Chloride	93 R	L		94 - 112	mmol/L	
> :0V	© 2018 Covance Laboratories	Inc. All rights	ta 2 DEF456	wanna No -		(Feed)	eneral	Seneral Train	Ten	ms and Condit	tions Privacy Policy C s Norton - LC	Contact
> ○ V ← HOME		Be Inve Disclaime	ta 2 DEF456 stigator: Dr Co	wance No.: d in on-screen re	suits is not intended to be	General General Manuals a replacement of the official La	General Communications ab Results, Alerts,	General Train Materials Data Revisi	Ter ing Rep ons and Cancellations	Louis	tions Privacy Policy C s Norton    LC Lab Reports section of	Contact DGOU1 this
> <- HOME		Be Inve Disclaime software a	ta 2 DEF456 stigator: Dr	wance No d in on-screen re ts should not be	sults is not intended to be used for patient diagnosis	eerer Manuas a replacement of the official Li treatment decisions or submit	Communications ab Results, Alerts, ssion to regulator	General Train Materials Data Revisi y bodies.	Ter ing Help ons and Cancellations	Louis found in the	ions Privacy Policy C s Norton • LC Lab Reports section of	Contact DGOU1 this
> СО V (- номе Д L	© 2018 Covance Laboratories	Be Inve Disclaime software a My Filters	ta 2 DEF456 stigator. Dr CC r: The information presente splication. On-screen result	wance No.: d in on-screen re ts should not be ••• sh	suits is not intended to be used for patient diagnosis ow filters 🗸	a replacement of the formation of submit	Communications ab Results, Alerts, ssion to regulator	General Tran Materials Data Revisi y bodies.	Ten ing Help ons and Cancellations	ms and Condit	tions Privacy Policy C s Norton    LC Lab Reports section of	Contact DGOU1 this
> СОV ← номе ▲ L Е L	e 2018 Covance Laboratories I c Lab Reports Lab Manuals	Be Inve Disclaime software a My Filters	reserved. Version 01.02.00	wance No.: d in on-screen re ts should not be sh	sults is not intended to be used for patient diagnosis ow filters	a replacement of the official Li treatment decisions or submit	Communications ab Results, Alerts, ssion to regulator	General Tran Materials Data Revisi y bodies.	Ter	Louis Louis found in the	s Norton • LC	Contact DGOU1 this
> <0∨ <+HOME ▲ L ↓ S	e 2018 Covance Laboratories I E Lab Reports Lab Manuals Site Actions	Be Inve Disclaime software a My Filters Search	reserved. Version 01.02.00	wance No.: d in on-screen re ts should not be sh	suits is not intended to be used for patient diagnosis ow filters v × Canceled result	a replacement of the official La treatment decisions or submit	Communications ab Results, Alerts, ssion to regulator	General Train Material Data Revisi y bodies.	Ten ing Help ons and Cancellations Not applicable R	Louis Louis found in the Resistant	ions Privacy Policy C s Norton • LC Lab Reports section of S Susceptible	Contact DGOU1 this
> <0 V ← HOME ↓ L ↓ S ↓ S	e 2018 Covance Laboratories I cancel aboratories I cancel aboratories Lab Reports Lab Manuals Site Actions Site Communications	Be Inve Disclaime software a My Filters Search Subject	reserved. Version 01.02.00	wance No.: d in on-screen re ts should not be sh nale (7) R	suits is not intended to be used for patient diagnosis ow filters v × Canceled result	a replacement of the official L treatment decisions or submit	Communications ab Results, Alerts, ssion to regulator	General Tola Materials Data Revisi y bodies. e NA M	Ten Hep Hot applicable R	Louis Louis found in the Resistant	ions Privacy Policy C s Norton - LC Lab Reports section of S Susceptible	Contact DGOUT this
> OV ← HOME ▲ L ■ L ■ L ■ S ■ S ■ S	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site Actions Site Communications Training Materials	Be Inve Disclaime software a My Filters Search Subject B Visit:	ta 2 DEF456 stigator Dr CCC r. The information presente pplication. On screen result	wance No.: d in on-screen re ts should not be should not be	suits is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official L1 treatment decisions or submit	Communications ab Results, Alerts, ssion to regulator	General Train Materiala Data Revisi y bodies. e NA N	Ter ing Rep ons and Cancellations Not applicable R	Louis Louis found in the l	s Norton  Ltb Reports section of S Susceptible	Contact DGOU this
<ul> <li>&gt;</li> <li>&gt;</li></ul>	e 2018 Covance Laboratories I     Covance Laboratories I     Lab Reports     Lab Manuals     Site Actions     Site Actions     Training Materials     Standard Tose Results	Be Inve Disclaime software a My Filters Search Subject Subject State Tess	reserved. Version 01.02.00 ta 2 DEF456 stigator: Dr. CC The information presente policiation. On-screen resul : 11 years Fet RETREATI RETREATMENT A croup: URINE CULTURE &	vance No.: d in on-screen re ts should not be male (7) <sup>R</sup> SSESSMENT, Apr SENSITIVITY (1)	sults is not intended to be used for patient diagnosis ow filters ~ X Canceled result 5, 2017 10:48 AM	a replacement of the official L2 treatment decisions or submit A Data revision occurred (1) A	Communications ab Results, Alerts, ssion to regulator	General Tour Materials Data Revisi y bodies.	Ter Rep dot applicable R	Louis Louis found in the	s Norton • LC Lab Reports section of S Susceptible	Contact DGOU1 this
<ul> <li>&gt;</li> <li>&gt;</li></ul>	2018 Covance Laboratories I     2018 Covance Laboratories I     Lab Reports     Lab Reports     Lab Manuals     Site Actions     Site Communications     Training Materials     Standard Test Results	Be Inve Disclaime software a My Filters Search B Subject B Visit: B Tess B Sp	reserved. Version 01.02.00 ta 2 DEF456 sogutor: Dr. Ccc The information presente pipelication. On-screen result The screen result of croup: URINE CULTURE & Group: URINE CULTURE & sections: Catheterized uring	vance No.: d in on-screen rets should not be where the should not be male (7) R SSESSMENT, Apr SENSITIVITY (1) (2) K	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official Li treatment decisions or submit	Communications be Results, Alerts, ssion to regulator	General Fair Materials Data Revisi y bodies.	Ter	Louis Louis found in the	s Norton • LC Lab Reports section of S Susceptible	Contact DGOUI this
> COV CHOME L L L L L L L L L L L L L	e 2018 Covance Laboratories I can be a constructed by the construction of the constru	Be Inve Disclaime software a My Filters Search B Subject B Visit: B Tess B Sp	esserved. Version 01.02.00 ta 2 DEF456 signato: Dr. CCC The information presente poplication. On screen resul to a construction of the constructio	wance No.: d in on-screen ret s should not be sh male (7) R SSESSMENT, Apr SENSITIVITY (1) (2) II	sults is not intended to be used for patient diagnosis ow filters Canceled result 5, 2017 10:48 AM	A Data revision occurred	Communications Communications Sister to regulated	General Tod Materials Data Revisi y bodies. e NA M MIC Panel	Ter mg Hep ons and Cancellations tot applicable R Disk Diffusion	Louis Louis found in the Panel	s Norton	Contact OGOUT this
→ → → → → → → → → → → → → →	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site Actions Site Actions Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Disclaime Software a My Filters Search Subject B Subject B Sister Search Subject B Search B Sp	reserved. Version 01.02.00 ta 2 DEF456 stigato: Dr CC The information presente pipilication. On screen result :	wance No.: din on-screen re is should not be sis should not be sis sis should not be sis sis should not be sis sis sis sis sis sis sis sis sis sis	sults is not intended to bo used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official L treatment decisions or submit	Communications bb Results, Alerrs siston to regulator	General Tod Materials Data Revisi y bodies. e NA M MIC Panel ug/ml	Ter Hep tot applicable R Disk Diffusion Interp. mm Interp	Louis Louis found in the Resistant Panel	s Norton • LC Lab Reports section of S Susceptible	Contact DOGOUI this
→ ←HOME ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	2018 Covance Laboratories I     2018 Covance Laboratories I     Lab Reports     Lab Manuals     Site Actions     Site Actions     Site Communications     Training Materials     Standard Test Results     Microbiology Results     Subjects	Be Inve Disclaime software i My Filters Search Subject B Visit: B Sc Sc Sc	reserved. Version 01.02.00 ta 2 DEF456 stigator: DrCc r. The information presente r. The information presente r. The provide the complexity of the complexity r. The stigation of the complexity of t	wance No.: d in on-screen re is should not be should not be should not be should not be should not be statement of the statement o	sults is not intended to be used for patient diagnosis ow fikers ~ X Canceled result 5, 2017 10:48 AM	a replacement of the official L1 treatment decision or submit A Data revision occurred (1) A <u>Drug/n</u> Ampic	communications communications bib Résults, Alerts sision to regulator	General real Materials Data Revisi y bodies. e NA N MIC Panel ug/ml >64	Ter Rep dot applicable R Disk Diffusion interp. mm Interp. R	Louis Condit Louis Condition Conditi	s Norton • LC Lab Reports section of S Susceptible	Contact DGOUI this
→ <p< td=""><td>e 2018 Covance Laboratories I     Covance Laboratories I     Lab Reports     Lab Manuals     Site Actions     Site Actions     Site Communications     Training Materials     Standard Test Results Microbiology Results     Subjects</td><td>Be Inve Disclaime software a My Filters Search Search Subject Bistis Search Subject Bistis Search</td><td>reserved. Version 01.02.00 ta 2 DEF456 stigator: Dr. CC E. The information presentes in the information presentes policitation. On-screene result is version of the information of the stigator of the information of the information of the information of the information of the information of the information of the information of the info</td><td>vance No.: in on-screen retes should not be should not be make (7) R SSESSMENT, Apr SSESSMENT, Apr SENSITVITY (1) (2) II</td><td>sults is not intended to be used for patient diagnosis ow filters ~ X Canceled result 5, 2017 10:48 AM</td><td>a replacement of the official Li treatment decisions or submit</td><td>Communications bib Results, Alerts sion to regulator</td><td>e NA MIC Panel ug/ml &gt;&gt;64 8/4</td><td>Ter Ter Ter Ter Ter Ter Ter Ter</td><td>Louis found in the i Resistant Panel</td><td>s Norton • LC Lab Reports section of S Susceptible</td><td>Contact DGOUI this</td></p<>	e 2018 Covance Laboratories I     Covance Laboratories I     Lab Reports     Lab Manuals     Site Actions     Site Actions     Site Communications     Training Materials     Standard Test Results Microbiology Results     Subjects	Be Inve Disclaime software a My Filters Search Search Subject Bistis Search Subject Bistis Search	reserved. Version 01.02.00 ta 2 DEF456 stigator: Dr. CC E. The information presentes in the information presentes policitation. On-screene result is version of the information of the stigator of the information of the information of the information of the information of the information of the information of the information of the info	vance No.: in on-screen retes should not be should not be make (7) R SSESSMENT, Apr SSESSMENT, Apr SENSITVITY (1) (2) II	sults is not intended to be used for patient diagnosis ow filters ~ X Canceled result 5, 2017 10:48 AM	a replacement of the official Li treatment decisions or submit	Communications bib Results, Alerts sion to regulator	e NA MIC Panel ug/ml >>64 8/4	Ter Ter Ter Ter Ter Ter Ter Ter	Louis found in the i Resistant Panel	s Norton • LC Lab Reports section of S Susceptible	Contact DGOUI this
→ → → → → → → → → → → → → →	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site	Be Inve Disclaime software i My Filters Search B Subject B Visit: B Test B Sp	reserved. Version 01.02.00 ta 2 DEF456 sityato: DrCC The information presente the poplication. On screen resul :T years Fer RETREATI RETREATMENT A :T years Fer RETREATI RETREATMENT A :T years Fer RETREATI RETREATMENT A :T years Fer Corganism 1: Sccherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen re ts should not be should not be sh	sults is not intended to be used for patient diagnosis ow filters v X Canceled result 5, 2017 10:48 AM	a replacement of the official L treatment decisions or submit      A Data revision occurred      (1) A      Drug/ Ampic Ampic Cettaz	Lintermediat	e NA MIC Panel ug/ml >64 8/4 0.5	Ter me hep tot applicable R Disk Diffusion nterp. mm Interp R S S	Louis found in the Resistant Panel	s Norton	Contact DGOUT this
→ → → → → → → → → → → → → →	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site Actions Site Actions Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Disclaime software a My Filters Search Subject Stablect Stablect Stablect Stablect Stablect Stablect Stablect Stablect	reserved. Version 01.02.00 ta 2 DEF456 suparo: DrCCc . The information presente- trapplication. On screen result :Tiperare Fer RETREAT1 RETREATMENT A Group: UNINE CULTURE & Group: UNINE CULTURE & Organism 1: Escherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen rais ts should not be male (7) // SSESSMENT, Apr SENSTIVITY (1) // // // //	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official L     retartment decisions or submit      A Data revision occurred      (1) A      Drugg      Ampic      Annox      Centax      Centax	Communications bb Results, Alerts sison to regulator	General Totar Revisit y bodies. e NA M MIC Panel ug/ml >64 8/4 0.5 16	Ter Hep tot applicable R Disk Diffusion Interp. mm Interp R S S	E Louis found in the Resistant	s Norton • LC Lab Reports section of S Susceptible	Contact DGOUT this
→ → → → → → → → → → → → → →	2018 Covance Laboratories I	Be Inve Disclaime Software 2 Search Subject Search Subject Search Subject Search Subject Search	reserved. Version 01.02.00 ta 2 DEF456 stigator: DrCC r. The information presente t: r. The information presente t: r. Thy args Fee t: r. Thy args Fee tectmer: Catheterized urine tectmer: Catheterized urine tectmer: Catheterized urine catheterized urine tectmer: Set tectherized urine tectherized	wance No.: d in on-screen re is should not be should not be should not be state of the second should be second sh	sults is not intended to be used for patient diagnosis ow fikers ~ X Canceled result 5, 2017 10:48 AM	a replacement of the official treatment decisions or submit treatment decisions or submit A Data revision occurred (1) A (1) A Drug/ Ampic Ampic Ceftar Ceftar	Communications bb Results, Alerts sion to regulator l Intermediat dent dillin/clavulanate idilme idilme	e NA MIC Panel ug/ml 1 >64 8/4 0.5	Ter Hep ons and Cancellations tot applicable R Disk Diffusion Interp. mm Interp S S 1 0	Louis found in the Resistant Panel	s Norton	Contact DGOUI this
	e 2018 Covance Laboratories I CARCEE tab Reports Lab Reports Lab Manuals Site Actions Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Disclaime Software a My Filters Search Subject Statistics Search Subject Statistics Sp	reserved. Version 01.02.00 ta 2 DEF456 stigator: Dr. CCC The information presente papplication. On-screen result The information presente papplication. On-screen result The information presente Th	wance No.: d in an screen re tes should not be st should not be male (7) // should not be SSESSIMUTY (1) (2) // .	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	A replacement of the official Li     treatment decisions or submit      A Data revision occurred      (1) A      Trugg      Ampox      Ceture      Ceture	Communications bib Results, Alerts sison to regulator 1 Intermedial Ngent Illin Illin Illin/clavulanate idime exime (oral) fothin	Germanian Data Revisia y bodies. e NA M MIC Panel ug/ml >64 8/4 0.5 16 32	Ter Ter Ter Ter Ter Ter Ter Ter	E Louis Could in the second s	s Norton  LC Lab Reports section of S Susceptible	Contact DGOUI this
	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site	Be Inve Disclaime software 4 My Filters Search W Sitt B Test B Sp	reserved. Version 01.02.00 ta 2 DEF456 sityato: DrCC The information presente pipilication. On screen resul :T years Fer RETREATI RETREATMENT A : Group: URINE CULTURE & : Group: URINE CULTURE & Group: URINE CULTURE & Group: URINE CULTURE & Group: URINE CULTURE & Growth: >=100,000 CFU/ml	wance No.: d in on-screen re- ts should not be should not be should not be should not be should not be should not be should not be seesing the should be seesing the should be gradient of the should be seesing the should be should be seesing the should be seesing the should be should be seesing the should be should be should not be	sults is not intended to be used for patient diagnosis ow filters v X Canceled result 5, 2017 10:48 AM	a replacement of the official L treatment decisions or submit A Data revision occurred (1) R Drug/ Ampic Ampic Cefur Cepha Nitroff	Communications to Desuits, Alerts sision to regulator I Intermediat Illin Clini/Clavulanate Idlin/Clavulanate Idline Iothin Iarantoin	Generatives           Data Revisi           Data Revisi           y bodies.           e         NA           MIC Panel           ug/ml           >64           8/4           0.5           16           32           8	Ter Hep tot applicable R Disk Diffusion Interp. mm Interp R S S I R S	Louis found in the i Resistant Panel	s Norton • LC Lab Reports section of S Susceptible	Contact OGOU!
→ VO: L L L L L L L L L L L L L L L L L L L	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals • Site Actions. Site Actions. Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Disclaime Software i My Filters Search Subject B Subject B Subject B Subject B Sp	reserved. Version 01.02.00 ta 2 DEF456 suppare: DrCore r: The information preserve pilcation. On screen result :: r: ? Ti years Fer RETREATI RETREATMENT A Group: UNINE CULTURE & exectmen: Catheterized unine Organism I: Escherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen fre s should not be male (7) R SSESSMENT, Apr SENSITIVITY (1) (2) II SENSITIVITY (1)	sults is not intended to be used for patient diagnosis ow fikers X Canceled result 5, 2017 10:48 AM	a replacement of the official Li treatment decisions or submit A Data revision occurred (1) A	Communications bb Results, Alerts sison to regulator 1 Intermediat Clim/clavulanate Idlim/ Clim/clavulanate Idlime iorinin urantoin hr/Sulfa	MIC Panel           ug/ml           >>64           8/4           0.5           16           32           8           >>16/304	Ter Hep tot applicable R Disk Diffusion Interp. rm Interp R S S S I R S S	ms and Condit  Louis found in the Resistant Panel	s Norton • LC Lab Reports section of S Susceptible	Contact OGOU this
→ VO: 1 ▲ 2 ▲ 2 ≪ 3 ↔	2018 Covance Laboratories I     2018 Covance Laboratories I     Lab Reports     Lab Reports     Lab Manuals     Site Actions     Site Actions     Site Communications     Training Materials     Standard Test Results     Microbiology Results     Subjects	Be Inve Software a My Filters Subjection Sub	reserved. Version 01.02.00 ta 2 DEF456 stigator: DrCC r: The information presente r:	vance No.: d in on-screen re te solution to the solution to the solution to the solution to the solution to the solution to the set of the solution to the solution tothe solution to the solution to the solution to the	sults is not intended to be used for patient diagnosis ow fikers ~ X Canceled result 5, 2017 10:48 AM	a replacement of the official treatment decisions or submite     A Data revision occurred     (1) A	Communications bb Results, Alerts sison to regulation 1 Intermediat dent cellin/clavulanate idime collin/clavulanate idime tothin collin/clavulanate idime tothin tothin thySulfa	Comparison     C	Ter Hep Oris and Cancellations Not applicable R Disk Diffusion nterp. mm Interp R S S S R R R R	ms and Condit  Louis found in the f Resistant  Panel  .	s Norton	Contact DGGOUT this
	e 2018 Covance Laboratories I     e     Lab Reports     Lab Manuals     istic Actions     Site Actions     Site Communications     Training Materials     Standard Test Results     Microbiology Results     Subjects	Be Inve Disclams software ar My Filters Search B Subject B Subject B Test B Se S	reserved. Version 01.02.00 ta 2 DEF456 sityato: DrCC The information presente the information presented the information presente the in	wance No.: d in on screen re to should not be so should not be male (7) R SSESSMURT, Apr SSESSITIVITY (1) (2) W :	sults is not intended to be used for patient diagnosis ow filters v X Canceled result 5, 2017 10:48 AM	A replacement of the official L treatment decisions or submit A Data revision occurred     (1) A	Vent	MIC Panel           ug/ml           >>64           16           32           >>64/2	Ter Ter Ter Ter Ter Ter Ter Ter	ms and Condit  Louis found in the s  Resistant  Panel  .	s Norton • LC Lab Reports section of S Susceptible	Contact DGGOUT this
	e 2018 Covance Laboratories I CARCE. E Lab Reports Lab Manuals Site Actions Site Actions Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Discalance software a My Filters Subject Subje	reserved. Version 01.02.00 ta 2 DEF456 stigato: DrCC The information presente pipilication. On-screen resul :T years Fer RETREATI RETREATMENT A Group: UNINE CULTURE & Group: Scherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen rs is should not be male (7) R SSESSMENT, Apr SSESSMENT, Apr (2) W :	sults is not intended to bo used for patient diagnosis ow filters Canceled result 5, 2017 10:48 AM	A replacement of the official L treatment decisions or submit Data revision occurred     (1) R     Deta     Deta     Control     Contro     Control     Control     Control     Control     Control	Communications bb Results, Alerts sision to regulation in Intermediat lillin communication lillin communication lindin iothin urantoin hr/Suffa juria liav hem	MIC Panel           wg/ml         1           >64         1           8/44         1           16         32           18         1           16         1           32         2           6/4/2         0.12	Ter Hep tot applicable R Disk Diffusion Interp. mm Interp R S S S S R R R R S S S S S S S S S S	E Louis Loui	s Norton • LC Lab Reports section of S Susceptible	Contact DGGOU this
→ ← Howe ←	¢ 2018 Covance Laboratories I CARCE. ¢ Lab Reports Lab Manuals § Site Actions Site Actions Site Actions Site Communications Standard Test Results Microbiology Results Subjects	Be Inve Disclame software a Search Subject Start Fres Sp Subject Start S	reserved. Version 01.02.00 ta 2 DEF456 stipato: DrCCc The information presente- inplication. On screen result :Ti years Fer RETREATI RETREATMENT A Group: UNINE CULTURE & Group: UNINE CULTURE & Corgonism 1: Escherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen rais is should not be male (7) R SSESSMENT, Apr SSESSMENT, Apr SSESSMENT, Apr B SSESSMENT, Apr B SSESSMENT, Apr B SSESSMENT, Apr B SSESSMENT, Apr B SSESSMENT, Apr SSESSMENT, Apr	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	A replacement of the official treatment decisions or submit A Data revision occurred     (1) A     Deta revision occurred     (1) A     Drugg     Ampic	Communications bb Results, Alerts sision to regulated the sision to regulated	MIC Panel           with C Panel	Ter Hep tot applicable R Disk Diffusion nterp. mm interp R S S S I R R R R R R R R R R R	E Louis Louis found in the Resistant Panel	s Norton • LC Lab Reports section of S Susceptible	Contact DGGOUT this
	e 2018 Covance Laboratories I CARCEE tab Reports Lab Manuals Site Actions Site Actions Site Communications Training Materials Standard Test Results Microbiology Results Subjects	Be Inve Discalance software as My Filters Search Subject Start Fast Special Sp	reserved. Version 01.02.00 ta 2 DEF456 stigato: DrCar ta 7 DEF456 stigato: DrCar results construction on screen result construction on	wance No.: d in on-screen rs is should not be male (7) R SSESSMENT, Apr SSESSMENT, Apr (2) W :	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official L treatment decisions or submit A Data revision occurred (1) A Drug/ Ampic Ampic Ampic Ampic Ampic Ampic Ampic Ampic Cetur Cepha Nuroft Tirame Tetar Copol Nuroft Tirame Tetar Copol	Communications     Communications     Dis Results, Alerts     Sision to regulation      Intermediat	MIC Panel           with C Panel	Ter Hep tot applicable R Disk Diffusion nterp. mm interp R S S I R R R S R R R R R R R R	ms and Condit  Louis found in the  Resistant  Panel	s Norton • LC Lab Reports section of S Susceptible	OGOU 
> COV C+HOME C C C C C C C C C C C C C C C C C C C	2018 Covance Laboratories I     2018 Covance Laboratories I     Lab Reports     Lab Reports     Lab Manuals     Site Actions     Site Actions     Training Materials     Standard Test Results     Microbiology Results     Subjects	Be Inve Discalar Software at Software at S	reserved. Version 01.02.00 ta 2 DEF456 suppare: PrCc r. The information present polication. On screen resul : r Ti years Fer RETREATI RETREATMENT A Group: UNINE CULTURE & teccimen: Catheterade unine Organism 1: Escherichia co Growth: >=100,000 CFU/mil	wance No.: d in on-screen fre should not be should not be ssessment, Apr SERSTWITY (1) (2) 11 12 12 12 12 12 12 12 12 12	sults is not intended to be used for patient diagnosis ow filters X Canceled result 5, 2017 10:48 AM	a replacement of the official Viceover treatment decisions or subbink  A Data revision occurred  (1) A  Proge Ampic Ampic Ampic Ampic Cefura Cefura Cefura Cefura Tetraa Tetraa Tetraa Tetraa Tetraa (Cipref (1)  Permee (1)	Communications bb Results, Alerts sision to regulation and the second second second and the second second second second second second second second second second second second second second second second second second second s	MIC Panel           www.com/second           e         NA P           // Mic Panel           www.com/second           // Mic Panel           // With Panel <td>Ter Hep ons and Cancellations dot applicable R Disk Diffusion interp. mm interp R S S S I I R R R R R R R R R R R R R R</td> <td>ms and Condit  Louis found in the I  Resistant  Panel  . </td> <td>s Norton • LC Lab Reports section of S Susceptible</td> <td>Contact DGOU This</td>	Ter Hep ons and Cancellations dot applicable R Disk Diffusion interp. mm interp R S S S I I R R R R R R R R R R R R R R	ms and Condit  Louis found in the I  Resistant  Panel  .	s Norton • LC Lab Reports section of S Susceptible	Contact DGOU This
	e 2018 Covance Laboratories I     e     Lab Reports     Lab Manuals     e     Site Actions     Site Actions     Site Communications     Training Materials     Standard Test Results     Microbiology Results     Subjects	Be Inve Disclame Software re Software software Software software Software software S	reserved. Version 01.02.00 ta 2 DEF455 signato: DrCC The information presente pipplication. On screen resul :T1 years Fer RETREATI RETREATMENT A : Group: URINE CULTURE & ecimen: Catheerized urine Organism 1: Escherichia co Growth: >=100,000 CFU/mil Final Report Enal Report RETREATURENT A RETREATMENT A	vvance No.: d in an screen re ts should not be male (7) R SSESSMENT, Apr SSESSMENT, Mars SSESSMENT, Mars SSESSMENT, Mars	sults is not intended to be used for patient diagnosis ow filters Canceled result 5, 2017 10:48 AM	A replacement of the official training of	Vent	Image: Constraint of the second sec	Ter Ter Ter Ter Ter Ter Ter Ter	ms and Condit  Louis found in the s  Resistant  Panel  .	ions Privacy Policy C s Norton • LC Lab Reports section of S Susceptible	OGOU1

Figure 3. Xcellerate Investigator Portal (XIP) standard test results (top) and microbiology (bottom) views.

consists of a monolithic RESTful web application programming interface (API) that provides endpoints to support reads and updates of the relevant underlying data. In addition, several independent back-end services for file upload, notifications, and user provisioning were retained from the legacy ESA application to provide continuity; the services for report delivery were completely rewritten to allow the system to perform at the required maximum capacity. Finally, the presentation layer consists of a browser-based, single-page application (SPA) that was designed to take advantage of the capabilities of modern browsers and primarily designed for desktop- or large tablet–sized devices.

## Physical Architecture

The protocol data warehouse is an Oracle relational database<sup>14</sup> composed of multiple physical schemas that separate data by function: security, protocol definition, and report



Figure 4. Xcellerate Investigator Portal (XIP) standard test results trend view.

metadata. The laboratory result data warehouse is an IBM Informix<sup>15</sup> relational database. Both warehouses get frequent (mini-batch) updates via ETLs (extract, transform, and load procedures) from the Zavacor system. For the application-specific database, we chose to use the existing Oracle database for convenience and compatibility with the legacy applications and services which were not being replaced. In addition to creating new database tables to support new features in the application, we also implemented a view abstraction layer and materialized views to improve query performance on large datasets.

The RESTful API was built using ASP.NET.<sup>16</sup> A Command Query Responsibility Segregation (CQRS) pattern<sup>17</sup> was used to separate the read and update models with the primary purpose of optimizing read performance in the reporting modules of the application. The CQRS model was built on top of the Dapper simple object mapper for .Net<sup>18</sup> instead of using a "heavy" object relational mapping (ORM)<sup>19</sup> layer. We have found that the transparency and ease of query implementation improve maintainability and allow data engineers to more easily contribute to development efforts.

Other application-layer services were written in .Net as follows:

 zReporting Services: Report-processing services that receive report messages in JavaScript Object Notation (JSON) format from Zavacor, convert them to HTML and PDF, save the files to a file share, and insert document metadata into the warehouse. The zReporting services are implemented as a set of .Net Web Services using the Hangfire.IO library<sup>20</sup> to ensure that all required tasks are queued and completed as expected.

- Notification Service: A scheduled Windows service that sends out instant notifications and daily digests based on protocol and user preferences.
- 3. File Upload Service: A scheduled Windows service that provides semi-automated upload capabilities for lab manuals and training material documents.
- 4. Provisioning Services: A set of scheduled Windows services that allow authorized internal users to request access on behalf of site users and have those requests automatically fulfilled without further human intervention for each user provisioning event.

The presentation layer was designed as a JavaScript Single Page Application (SPA)<sup>21</sup> and built using Angular,<sup>22</sup> a TypeScript-based, open-source, front-end web application platform led by the Angular Team at Google and by a community of individuals and corporations. Other third-party open-source and commercial JavaScript libraries were also used: Material Design Lite<sup>23</sup> was used for the base component and layout framework, and ag-Grid<sup>24</sup> was used for all data grid implementations in the application. For visualizations, we used our proprietary D3.js-based<sup>25</sup> library that we originally developed for our Xcellerate Medical Review

	results should not be used for patient	nt diagnosis, treatr	nent decisions or sub	omission to regulatory bodies.				
A	Subject: 001 - HFJ 🛛 👻	Gender:	emale Initial	s: HFJ Age: 39 years				
5	TABLE CHART						Flagged values	SI Units
Ū.						R Data revi	ision occurred 🛛 💐 Administrative C	Question •••
<b>1</b>	Test	Range	Units	VISIT 1 Jun 27, 2013 7:20 PM	VISIT 2 Jun 30, 2013 8	8:00 AM	VISIT 3 Jul 1, 2013 8:00 AM	
0	E Test Group: ELECTROLYTE PANE	1. (5)		L718385	M174171		M174434	
	Magnesium	0.62 - 1.27	mmol/L	0.53 L	1.19		1.19	
-	Serum Sodium	132 - 147	mmol/L	140	141		141	
	Serum Potassium	3.4 - 5.4	mmol/L	3.2 L	3.6		3.6	
	Serum Bicarbonate	17 - 30.6	mmol/L	20.0	22.8		22.8	
	Serum Chloride	94 - 112	mmol/L	92 L	91 L		91 L R	
	Test Group: FEMALE OF CHILDBI	EARING POT.? (1)						
	Pt. of childbearing potential?			YES				
	Test Group: HEMOGLOBIN A1C	(1)						
	Hemoglobin A1c,Variant(-70)	<6.5%					7.0 H N	
	Test Group: LACTIC ACID (1)						2011 8	
	Lactate, NaFI/KOx pl	0.4 - 2.2	mmol/L		3.0 H		3.0 H *	
çov	© 2018 Covance Laboratories Inc. All ri	ghts reserved. Ver	sion 01.02.00	ory Services eSITE TST			Terms and Conditions Priv	<ul> <li>vacy Policy Contact Us</li> <li>LOGOUT</li> </ul>
, cov 4	© 2018 Covance Laboratories Inc. All ri ANCE. Disclamer: The information present results should not be used for patie Subject: 002 - JRH	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, treatr Gender: F	sion 01.02.00  ntral Laborato ew Durkee (Inv) - Covan sults is not intended ment decisions or sub female Initial	Dry Services eSITE TST rec No. 501349 to be a replacement of the official mission to regulatory bodies. 5:: JRH Age: 43 years	ERE Server Manuas ab Results, Alerts, Data Revisions and	General Training Communications Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT
, COV ∉ ∎∎	© 2018 Covance Laboratories Inc. All rights of the second	ghts reserved. Ver Covance Ce Investigator: Matthi ted in on-screen re nt diagnosis, treatr Gender: F	ntral Laborato ev Durkee (Inv) - Covan sults is not intended nent decisions or sub <b>Female</b> Initial	bry Services eSITE TST to be a replacement of the official I mission to regulatory bodies. ≲ JRH Age: 43 years	ab Results, Alerts, Data Revisions and	Common server Common server Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT     SI Units     Contact Us
> COV € ∎	© 2018 Covance Laboratories Inc. All rights of the second	ghts reserved. Ver Covance Ce Investigator: Matth- ted in on-screen re nt diagnosis, treatr Gender: F	sion 01.02.00  Intral Laborato ex Durkee (Inv) - Covan suits is not intended ment decisions or suit Fremale Initial Tree form	Dry Services eSITE TST tere No.: 901349 tomission to regulatory bodies. S:: JRH Age: 43 years	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	very Policy Contact Us     LOGOUT     LOGOUT     SI Units
> COV € ∎ ∎	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search	ghts reserved. Ver Covance Ce Investigator: Matthi ted in on-screen re nt diagnosis, treatr Gender: F	sion 01.02.00  ntral Laboratt ev Durkee (Inv) - Covan suits is not intended ment decisions or suit feemale Initial Test Gro	Dry Services eSITE TST tec No: 901349 to be a replacement of the official I mission to regulatory bodies. S JRH Age: 43 years up	ab Results, Alerts, Data Revisions and	General Tarian General Matrix Cancellations found in the Lab	Terms and Conditions Priv	Key Policy Contact Us     LOGOUT     LOGOUT     SI Units     How III non-flagged     wr1
> COV & @ @ @	© 2018 Covance Laboratories Inc. All ri CANCE. Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search	ghts reserved. Ver Covance Ce Investigator: Matthi- ted in on-screen re nt diagnosis, treatr Gender: F	sien 01.02.00  Intral Laboratc w Durkee (inv) - Covan suits is nor intended ment decisions or suit Female Initial Test Gro	Dry Services eSITE TST ice No: 901349 to be a replacement of the official mission to regulatory bodies. s: JRH Age: 43 years	ab Results, Alerts, Data Revisions and	Concellations found in the Lab	Terms and Conditions Priv Prip Louis Norton D Reports section of this software appl Flagged values I flagged-high I flagged v	very Policy Contact Us     LOGOUT     LOGOUT     LOGOUT     SI Units     dow
> COV € ▲ ₽ ♥ ≈ (	D 2018 Covance Laboratories Inc. All re CARCE. Disclamer: The information present results should not be used for patien Subject: 002 - JRH TABLE CHART Search	ghts reserved. Ver Covance Ce Investigator: Math ted in on-screen re nt diagnosis, treatr Gender: F	sion 01.02.00  Intral Laboratco w Durkee (Inv) - Covan suits is not intended suits is not intended reenale Initial Test Gro	ory Services eSITE TST for No. 301349 to be a replacement of the official mission to regulatory bodies. s: JRH Age: <b>43 years</b> op.	Test	General Taiman General Taiman Cancellations found in the Lab	Terms and Conditions Priv Priv Prip Louis Norton Reports section of this software appl Fiagged values fiagged-high fing agged- v	Contact Us     LOGOUT     LOGOUT     Ilication. On-screen     SI Units     dow
> COV ← ▲ ■ ■ * *	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, treatr Gender: I Magnesium	sion 01.02.00  ntral Laboratc wo Durkee (Inv) - Covan suits is not intended ment decisions or suit iemale initial Test Gro Test Gro	Dry Services eSITE TST tere No.: 801349 to be a replacement of the official I mission to regulatory bodies. SE JRH Age: 43 years up.	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT     LOGOUT     LOGOUT     LOGOUT     LOGOUT     LOGOUT     Logo
> COV 4 4 9 2 2 3 3 3	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PAREL	ghts reserved. Ver Covance Ce Investigator: Matthi ted in on-screen re nt diagnosis, reading Gender: I Magnesium	sien 01.02.00  ntral Laboratc ev Durkee (Im) - Covan sults is nor intended ment decisions or sult eremale initial  Text Gro ser 1	Dry Services eSITE TST Ker No: 901349 to be a replacement of the official I mission to regulatory bodies. St JRH Age: 43 years up	ab Results, Alerts, Data Revisions and	Cancelladors found in the Lab	Terms and Conditions Priv	LOGOUT LLOGOUT SI Units How III non-flagged stra 1.15
> COV 4 10 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PAREL	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, reaction Gender: I Magnesium Serum Sodium	sien 01.02.00  ntral Laboratc ev Durkee (Imy) - Covan suits is nor intended ment decisions or suit eremale Initial Test Gra	Dry Services eSITE TST           Ker No: 901349           to be a replacement of the official I           mission to regulatory bodies.           %: JRH         Age: 43 years           upp	ab Results, Alerts, Data Revisions and	Cancelladors found in the Lab	Terms and Conditions Priv	LOGOUT LOGOUT lication. On-screen SI Units How III non-flagged stra 1.15
> COV 4 1 1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	© 2018 Covance Laboratories Inc. All re Discillamer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL	ghts reserved. Ver Covance Ce Investigator: Math- ted in on-screen re nt diagnosis, creen Gender: J Magneslum Serum Sodum	sien 01.02.00  Intral Laboratc ex Durkee (Inv) - Covan sults is not intended ment decisions or sult Fernale Initial Test Gro NoT 1	Dry Services eSITE TST tec No: 901349 to be a replacement of the official I mission to regulatory bodies. S: JRH Age: 43 years up:	ab Results, Alerts, Data Revisions and	Concellations found in the Lab	Terms and Conditions Priv Priv Louis Norton D Reports section of this software appl Flagged values Flagged values Flagged values V	Avery Policy Contact Us  LOGOUT LOGOUT LOGOUT SI Units Low III non-flagged form 1.15 1.46
> COV 4 10 2 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	© 2018 Covance Laboratories Inc. All ri CACCE. Disclasser: The information present results should not be used for patie Subject: OZ - JRH TABLE CHART Search ELECTROLYTE PANNEL	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, trreat Gender: I Magneslum Serum Sodum rum Potassium	sion 01.02.00  Intral Laboratc w Durkee (inv) - Covan suits is nor intended ment decisions or suit Female Initial  Test Gro	Dry Services eSITE TST ice No. 901349 to be a replacement of the official I mission to regulatory bodies. s: JRH Age: 43 years upp	ab Results, Alerts, Data Revisions and	Concellations found in the Lab	Terms and Conditions Priv Prip Louis Norton D Reports section of this software appl Flagged values flagged-high flagged- v	Avery Policy Contact Us  LOGOUT LOGOUT LOGOUT LICATION. On-screen SI Units Low Inon-flagged Kara LILIS LILI
> COV 4 4 9 7 7 3 3	Declarer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, treatr Gender: F Magnedum Magnedum Serum Sodum rum Potassium	sion 01.02.00  Intral Laborato ev Durkee (inv) - Covan suits is nor intended ment decisions or suit Female Initial Test Gro	Dry Services eSITE TST ser No. 501349 to be a replacement of the official mission to regulatory bodies. s: JRH Age: 43 years up.	Test	Contentions found in the Lab	Terms and Conditions Priv	LOGOUT LOGOUT lication. On-screen SI Units How III non-flagged sers 1.15 6.1
> COV 4 10 2 2 3 2 3 3 3	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Search	ghts reserved. Ver Covance Ce Investigator: Matthe ted in on-screen re nt diagnoist, con- Gender: J Magnesium Serum Sodium rum Potassium	sion 01.02.00  Intral Laboratc wo Durkee (Inv) - Covan usuts is not intended ment decisions or sub iemale initial  Test Gro  NST 1	Dry Services eSITE TST           tore No.: 801349           to be a replacement of the official I           mission to regulatory bodies.           \$5: JRH         Age: 43 years	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT LLOGOUT LLOGOUT SI Units SI Units Inon-flagged stars 1.15 146
> COV 4 1 0 2 3 3 3	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Se	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, reserved Gender: I Magneslum Serum Sodium um Potassium um Bisarbonate	sien 01.02.00  Intral Laboratc ev Durkee (Im) - Covan suits is nor intended ment decisions or suit eremale initial  Text Gro sort	Dry Services eSITE TST Ker No: 901349 to be a replacement of the official I mission to regulatory bodies. St JRH Age: 43 years upp	ab Results, Alerts, Data Revisions and	Cancelladors found in the Lab	Terms and Conditions Priv	LOGOUT LLOGOUT lication. On-screen SI Units How III non-flagged str3 
> COV 4 10 2 2 3 3 3	© 2018 Covance Laboratories Inc. All ri Disclassing of the information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Se Ser	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen In diagnosis, reach Gender: J Magnesium Serum Sodium Invun Potassium um Bicarbonate	sion 01.02.00  Intral Laboratc ex Durkee (inv) - Covan suits is not intended ment decisions or suit Female Initial Test Gro Not 1	Dry Services eSITE TST tec No: 901349 to be a replacement of the official I mission to regulatory bodies. S: JRH Age: 43 years upp	ab Results, Alerts, Data Revisions and	Concellations found in the Lab	Terms and Conditions Priv	Avery Policy Contact Us  LOGOUT LOGOUT LOGOUT SI Units Low III non-flagged first fill fill fill fill fill fill fill fil
> COV 4 10 3 2 3 3 3	D 2018 Covance Laboratories Inc. All ri Discularies The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Search	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, treat Gender: F Magnesium Serum Sodium um Pitassium um Bicarbonate	sion 01.02.00  Intral Laborated we Durkee (Iriv) - Covan usuits is nor intended ment decisions or sub Female Initial Test Gro	Dry Services eSITE TST ter No.: 601349 to be a replacement of the official i smission to regulatory bodies. St JRH Age: 43 years up	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT LOGOUT lication. On-screen St Units dow III non-flagged terrs 1.15
> COV € ▲ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Se	ghts reserved. Ver Covance Ce Investigator: Matthe ted in on-screen re nt diagnoisi, training Gender: F Magnesium Serum Sodium um Bicarbonate Serum Chloride	stion 01.02.00  Intral Laboratc wr Durkee (Inv) - Covan suits is not interded ment decisions or suit iemale initial  Test Gro  S871	bry Services eSITE TST tor No.: 801349 to be a replacement of the official I mission to regulatory bodies. 5: JRH Age: 43 years	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT LLOGOUT SI Units Itation. On-screen
> COV 4 1 1 7 7 6 	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PAMEL Ser	ghts reserved. Ver Covance Ce Investigator: Matthe Gender: I Magnesium Serum Sodium um Bicarbonate Serum Chioride	stien 01.02.00  Intral Laboratc ev Durkee (Im) - Covan sults is not intended Test of the	Dry Services eSITE TST Ker No: 901349 to be a replacement of the official I mission to regulatory bodies. St JRH Age: 43 years up	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT LOGOUT LOGOUT SI Units How III non-flagged srs1 
> COV ← ▲ ■ 令 ≈ ③	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLIVE PAMEL Ser Ser	ghts reserved. Ver Covance Ce Investigator: Matth ted in on-screen re nt diagnosis, reading and the screen re secure Chloride Att_Variant;70)	stien 01.02.00  Intral Laboratc ev Durkee (Im) - Covan sults is not intended Test of the	Dry Services eSITE TST Ker No: 901349 to be a replacement of the official I mission to regulatory bodies. St JRH Age: 43 years up	ab Results, Alerts, Data Revisions and	Cancellations found in the Lab	Terms and Conditions Priv	LOGOUT LOGOUT LOGOUT SI Units How III non-flagged srs1 
> COV 4 <b>A</b> <b>B</b> <b>A</b> <b>B</b> <b>A</b> <b>COV</b> 5 <b>X</b> (0) <b>X</b>	© 2018 Covance Laboratories Inc. All re Disclaimer: The information present results should information present Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Ser Ser Ser	ghts reserved. Ver Covance Ce Investigator: Math- ted in on-screen re nt diagnosis: Centre Gender: f Magneslum Serum Sodium Investore Chorde Serum Chloride Serum Chloride	sion 01.02.00  Intral Laborate ex Durkee (Inv) - Covan suits is nor intended Test Gro Test Gro Test Gro	Dry Services eSITE TST tec No: 901349 to be a replacement of the official I mission to regulatory bodies. Siz JRH Age: 43 years upp	ab Results, Alerts, Data Revisions and	Cancelladors found in the Lab	Terms and Conditions Priv	Ancy Policy Contact Us  LOGOUT LOGOUT LOGOUT SI Units LOGOUT LIS LOGUT LIS LOGUT LIS LOGUT LIS
> COV 4 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	© 2018 Covance Laboratories Inc. All ri Discillamer: The information present results should not be used for patie Subject: 002 - JRH TABLE CHART Search ELECTROLYTE PANEL Ser HEMO_MEMORPHICALON LATTICALON	ghts reserved. Ver Covance Ce Investigator: Math ted in on-screen fidiagnosis: and the screen Gender: J Magnesium serum Sodum rum Potassium um Bicarbonate Serum Chionse Att. Variant;-70) att. Naf/KCb of	sion 01.02.00  Intral Laborate ex Durkee (Inv) - Covan suits is not intended Test Gro Test Gro	Dry Services eSITE TST tec No: 901349 to be a replacement of the official I mission to regulatory bodies.	ab Results, Alerts, Data Revisions and	Cancelladors found in the Lab	Terms and Conditions Priv	Any Policy Contact Us  LOGOUT LOGOUT LOGOUT LOGUT LIS LIS LOGUT LIS

Figure 5. Xcellerate Investigator Portal (XIP) subject lab results (top) and subject test trends (bottom) views.

application.<sup>4</sup> Finally, for identity management and authentication, we used Okta,<sup>26</sup> an OpenID Connect<sup>27</sup> compliant cloud-based identity provider. All connections to the system are strictly required to be secure, incorporating strong Transport Layer Security (TLS) encryption for all traffic to and from the user's browser.

## Performance Considerations

XIP is used by more than 240,000 investigator staff worldwide on more than 1,800 studies containing greater than 30 million lab report and result alert documents. In addition to study-generated content, all usage and change history are



Figure 6. Xcellerate Investigator Portal (XIP) logical architecture.



**Figure 7.** Distinct monthly logins of the new Xcellerate Investigator Portal (XIP) and old eSiteAccess (ESA) legacy applications in 2018.

also tracked. With such large amounts of data, performance had to be designed into the system. We used a number of design elements to ensure that the visualizations and document lists load within the performance targets set for the application, including optimized database indexing; materialized views for common queries of slow-changing data; a high-performance micro-ORM data access layer; a CQRS pattern to optimize read queries; horizontally scalable, redundant application servers; a high-performance user interface data grid control; and stateless and asynchronous data flow by default in the application and presentation layers. The system as implemented has been considerably more responsive under load than its predecessor. At peak load, users are able to access the XIP application landing page 50% faster than the comparable ESA page. In addition, lab report access times are up to 80% faster, measuring consistently faster than 2 sec for typical usage scenarios. The fault-tolerant design allows for some system maintenance to be performed while the system remains active for end users, and reduced unplanned outages by more than 60% (comparing XIP availability in 2018 to ESA availability in 2017).

# **Results and Discussion**

The platform was introduced to Covance's investigator users in January 2018 by encouraging selected sites to try the new application while retaining access to the existing legacy system, as well as issuing accounts to new users and training them on the new platform first. User feedback was collected via directed surveys, and following positive response, a concerted effort to add more studies and users to the platform began within 3 months of launch. Usage of the new platform exceeded that of the legacy system in September 2018 and continues to grow rapidly (**Fig. 7**). The new Xcellerate Investigator Portal experiences less downtime, faster response time, and substantially fewer end-user support issues than the legacy system, resulting in improved user satisfaction.

# Conclusion

We have presented the technical underpinnings and user interface of a new web portal that allows secure online delivery of laboratory results, reports, manuals, and training materials to clinical trial sites. The system offers vastly improved capabilities and user experience without requiring any changes to the underlying acquisition systems and data stores. Planned enhancements include the implementation of additional features and enhancements for sponsor users, including a sponsor communication function, as well as online viewing of training materials and web content without the need to download the content locally.

#### Acknowledgments

We would like to thank the entire development team who contributed to the design, development, deployment, and support of the Xcellerate platform, as well as our internal and external users for their valuable suggestions and feedback.

#### **Declaration of Conflicting Interests**

The authors, all of whom were employed by Covance when the system was built, confirm that there are no known conflicts of interest associated with this publication, and there has been no significant external financial support for this work that could have influenced its outcome. No study sponsor has been involved in the design of the system; the collection, analysis, and interpretation of the data presented herein; the writing of the manuscript; or the decision to submit the manuscript for publication.

#### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

### **ORCID** iD

Dimitris K. Agrafiotis D https://orcid.org/0000-0002-5604-5692

#### References

- Wikipedia. Laboratory Information Management System. https://en.wikipedia.org/wiki/Laboratory\_information\_management\_system.
- 2. Wikipedia. Clinical Trial Management System. https:// en.wikipedia.org/wiki/Clinical\_trial\_management\_system.
- Covance. Covance Central Labs and Clinical Laboratory Services. https://www.covance.com/services/clinical-testing/ central-laboratory-services.html.
- Agrafiotis, D. K.; Lobanov, V. S.; Farnum, M. A.; et al. Risk-Based Monitoring of Clinical Trials: An Integrative Approach. *Clin. Ther.* 2018, 40, 1204–1212.

- McCaffrey, R. P.; Tevelev, B. M.; Yang, E.; et al. A Statistical Evaluation of Observed Risk Flux in RBM-Managed Clinical Trials. Submitted for publication.
- Farnum, M. A.; Mohanty, L.; Ashok, M.; et al. A Dimensional Warehouse for Integrating Operational Data from Clinical Trials. *Database*. 2019, 2019, baz039.
- Yang, E.; Scheff, J. D.; Shen, S. C.; et al. A Late Binding, Distributed, NoSQL Warehouse for Integrating Patient Data from Clinical Trials. *Database*. 2019, 2019, baz032.
- Farnum, M. A.; Ashok, M.; Kowalski, D.; et al. A Cross-Source, System-Agnostic Solution for Clinical Data Review. *Database*. 2019, 2019, baz017.
- 9. Ciervo, J.; Shen, S. C.; Stallcup, K.; et al. A New Risk and Issue Management System to Improve Productivity, Quality, and Compliance in Clinical Trials. *JAMIA Open.* **2019**, *2*, 216–221.
- Agrafiotis, D. K.; Simson, A.; Dai, H.; et al. Advanced Biological and Chemical Discovery (ABCD): Centralizing Discovery Knowledge in an Inherently Decentralized World. *J. Chem. Inf. Mod.* 2007, 47, 1999–2014.
- Farnum, M.; Lobanov, V. S.; Brennan, M.; et al. Clinical Case: Enhancing Medical Monitoring with Visualization and Analytics. Presented at 2012 IEEE International Conference on Bioinformatics and Biomedicine, Philadelphia, PA, 2012.
- Yang, E.; O'Donovan, C.; Phillips, J.; et al. Quantifying and Visualizing Site Performance in Clinical Trials. *Contemp. Clin. Trials Commun.* 2018, 9, 108–114.
- Cepeda, M. S.; Lobanov, V. S.; Farnum, M.; et al. Broadening Access to Electronic Health Care Databases. *Nature Rev. Drug Discov.* 2010, 9, 84.
- 14. Oracle. Oracle Database. https://www.oracle.com/database.
- 15. IBM. Informix. https://www.ibm.com/products/informix.
- Microsoft. ASP.NET. https://dotnet.microsoft.com/apps/ aspnet.
- 17. Wikipedia. Command Query Separation. https://en.wikipedia. org/wiki/Command-query\_separation.
- GitHub. Dapper—A Simple Object Mapper for .Net. https:// github.com/StackExchange/Dapper.
- Wikipedia. Object Relational Mapping. https://en.wikipedia. org/wiki/Object-relational mapping.
- 20. Hangfire. https://www.hangfire.io.
- Wikipedia. Single Page Application. https://en.wikipedia.org/ wiki/Single-page\_application.
- 22. Angular. https://angular.io.
- 23. Material Design Lite. https://getmdl.io.
- 24. ag-Grid. https://www.ag-grid.com.
- 25. Data Driven Documents. https://d3js.org.
- 26. Okta—The Identity Standard. https://www.okta.com.
- 27. OpenID Connect. https://openid.net/connect.